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Abstract 
 
Purpose:  Selective proteolytic activation of protease-activated receptor-1 (PAR1) by 
thrombin and matrix metalloproteinase-1 (MMP-1) plays a central role in enhancing 
angiogenesis. We investigated the expression levels of thrombin, MMP-1 and PAR1 and 
correlated these levels with vascular endothelial growth factor (VEGF) in proliferative 
diabetic retinopathy (PDR). In addition, we examined the expression of PAR1 and thrombin 
in the retinas of diabetic rats and PAR1 in human retinal microvascular endothelial cells 
(HRMEC) following exposure to high-glucose, the proinflammatory cytokines interleukin-1 
(IL-1) and tumor necrosis factor- (TNF-) and the hypoxia mimetic agent cobalt chloride 
(CoCl2).  
Methods: Vitreous samples from 32 PDR and 23 nondiabetic patients, epiretinal membranes 
from 10 patients with PDR, retinas of rats and HRMEC were studied by enzyme-linked 
immunosorbent assay (ELISA), immunohistochemistry and Western blot analysis. An assay 
for in vitro cell migration angiogenesis was performed in HRMEC.  
Results: In epiretinal membranes, PAR1 was expressed in vascular endothelial cells, CD45-
expressing leukocytes and myofibroblasts. ELISA and Western blot assays revealed 
significant increases in the expression levels of thrombin, MMP-1 and VEGF in vitreous 
samples from PDR patients compared to nondiabetic controls. Significant positive 
correlations were found between the levels of VEGF and the levels of thrombin (r=0.41; 
p=0.006) and MMP-1 (r=0.66; p<0.0001). Significant increases of cleaved PAR1 
(approximately 50 kDa) and the proteolytically active thrombin (approximately 50 kDa) were 
detected in rat retinas after induction of diabetes. The proinflammatory cytokines IL-1 and 
TNF-, but not high-glucose and CoCl2, induced upregulation of cleaved PAR1 
(approximately 30 kDa) in HRMEC. In addition, thrombin and MMP-1 induced VEGF in 
HRMEC and vorapaxar, a PAR1 inhibitor, inhibited thrombin-induced migration in HRMEC.  
 
Conclusions: Interactions between thrombin, MMP-1, PAR1 and VEGF might facilitate 
angiogenesis in PDR. 
 
Key words: proliferative diabetic retinopathy; angiogenesis; protease-activated receptor-1; 
thrombin; matrix metalloproteinase-1 
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Introduction 
Ischemia-induced angiogenesis, a process by which new blood vessels are formed 
from pre-existing ones, is a hallmark feature of proliferative diabetic retinopathy (PDR) and 
is a critical step in the progression of the disease. This process takes place as a consequence 
of an angiogenic switch, which allows the recruitment of blood vessels from neighboring 
tissues [1-3]. Vascular endothelial growth factor (VEGF) is the major angiogenic factor in 
PDR that promotes neovascularization and vascular leakage [4]. In addition, chronic, low-
grade subclinical inflammation is responsible for many of the vascular lesions in diabetic 
retinopathy [5-7]. The causal relationship between inflammation and angiogenesis is now 
widely accepted [8]. An emerging issue in diabetic retinopathy research is the focus on the 
mechanistic link between chronic, low-grade inflammation and angiogenesis.  Therapeutic 
regulation of angiogenesis is an attractive approach for the treatment of PDR [9]. To aid the 
progress of anti-angiogenic therapies, a more comprehensive understanding of molecules 
regulating angiogenesis in PDR is of value in order to identify additional therapeutic targets 
and to avoid potential detrimental side-effects. 
Protease-activated receptor-1 (PAR1) is a G protein-coupled receptor. This receptor 
carries its own ligand, which remains silent until the serine protease thrombin and other 
proteases cleave at a specific site within the extracellular N-terminus exposing a new N-
terminal-tethered ligand domain that binds and activates the cleaved receptor [10-12]. More 
recently, the zinc-dependent matrix metalloproteinase-1 (MMP-1) was identified as having 
the capacity to cleave and activate PAR1 [10-13]. Signal transduction initiated by PAR1 
activation has many downstream consequences, leading to changes in cellular morphology, 
proliferation, migration, and adhesion [10]. It was recently shown that selective proteolytic 
activation of PAR1 by thrombin and MMP-1 plays a central role in enhancing both 
angiogenesis and tumor growth [10, 13-18]. In addition, activation of PAR1 leads to 
synthesis and secretion of functional VEGF protein and that PAR1-induced angiogenesis is 
mediated by VEGF [17].  
Given the key roles of PAR1/ MMP-1/thrombin axis in angiogenesis, we investigated 
the hypothesis that this axis may be involved in the pathogenesis of PDR. To test this 
hypothesis, we investigated the expression of MMP-1, thrombin and PAR1 in the vitreous 
fluid and epiretinal fibrovascular membranes from patients with PDR and correlated MMP-1 
and thrombin levels with the levels of the angiogenic factor VEGF. In addition, to 
corroborate a functional link between this axis and diabetes, we investigated the expression of 
PAR1 and thrombin in the retinas of diabetic rats and PAR1 in human retinal microvascular 
endothelial cells (HRMEC) following exposure to high-glucose to replicate hyperglycemia, 
to the proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor- (TNF-
) as a means to mimic inflammation and to the hypoxia-mimetic agent cobalt chloride 
(CoCl2).  Finally, we further examined whether vorapaxar (formerly known as SCH530348), 
a potent PAR1 receptor antagonist [19], blocked thrombin-induced migration in HRMEC. 
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Materials and Methods 
Vitreous samples and epiretinal membranes specimens 
Undiluted vitreous fluid samples (0.3 – 0.6 ml) were obtained from 32 patients with 
PDR during pars plana vitrectomy. The indications for vitrectomy were tractional retinal 
detachment, and/or nonclearing vitreous hemorrhage. The control group consisted of 23 
patients who had undergone vitrectomy for the treatment of rhegmatogenous retinal 
detachment with no proliferative vitreoretinopathy. The duration of retinal detachment ranged 
from 2 to 11 days, with a mean of  5.9 ± 2.7 days. Controls were free from systemic disease. 
Vitreous samples were collected undiluted by manual suction into a syringe through the 
aspiration line of vitrectomy, before opening the infusion line. The samples were centrifuged 
(500 rpm for 10 min, 4C) and the supernatants were aliquoted and frozen at -80C until 
assay. Epiretinal fibrovascular membranes were obtained from 10 patients with PDR during 
pars plana vitrectomy for the repair of tractional retinal detachment. Membranes were fixed 
for 2 hours in 10% formalin solution and embedded in paraffin.  
The study was conducted according to the tenets of the Declaration of Helsinki. All 
the patients were candidates for vitrectomy as a surgical procedure. All patients signed a 
preoperative informed written consent and approved the use of the excised epiretinal 
membranes and vitreous fluid for further analysis and clinical research. The study design and 
the protocol were approved by the Research Centre and Institutional Review Board of the 
College of Medicine, King Saud University. 
Rat streptozotocin-induced diabetes model 
 All procedures with animals were performed in accordance with the ARVO 
statements for the use of animals in ophthalmic and vision research and were approved by the 
Institutional Animal Care and Use Committee of the College of Pharmacy, King Saud 
University. Adult male Sprague-Dawley rats, 8-9 weeks of age weighting in the range of 220-
250 g were overnight fasted and streptozotocin (STZ) (65 mg/kg in 50 mM sodium citrate 
buffer, pH 4.5; Sigma, St. Louis, MO) was injected intraperitoneally. Equal volumes of 
citrate buffer were injected in control non-diabetic animals. Measurement of blood glucose 
concentrations and body weight were started 3 days after injection of STZ. Diabetes was 
confirmed by assaying the glucose concentration in blood taken from the tail vein. Rats with 
glucose levels >250 mg/dl were categorized as diabetic. After 4 weeks of diabetes, animals 
were anesthetized by intraperitoneal injection of an overdose of chloral hydrate and sacrificed 
by decapitation. Retinas were dissected, flash frozen and stored at -70
0
C until use. Similarly, 
retinas were obtained from age-matched nondiabetic control rats. 
Cell culture  
Primary human retinal microvascular endothelial cells (HRMEC) were purchased 
from Cell Systems Corporation (Kirkland, Washington, USA) and maintained in complete 
serum free media (Cat. No. SF-4Z0-500, Cell System Corporation) supplemented with 
recombinant RocketFuel (Cat No. SF-4Z0-500, Cell System Corporation), CultureBoost (Cat. 
No. 4CB-500, Cell System Corporation) and antibiotics (Cat. No. 4Z0-643, Cell System 
Corporation) at 37°C in a humidified atmosphere with 5% CO2. We used HRMEC cells only 
up to passage 8 for all the experiments. When HRMEC cells became 80% confluent, cells 
were starved in minimal media (medium with antibiotics and 0.25% RocketFuel and without 
CultureBoost) overnight to eliminate any residual effects of growth factors. Following 
5 
 
starvation, HRMEC were either left untreated or treated either with 10 ng/ml of recombinant 
human (rh) IL-1 (Cat. No. 201-LB, R&D Systems, Minneapolis, MN), 30 ng/ml rh  TNF- 
(Cat. No. 210-TA, R&D Systems, Minneapolis, MN), rh IL-1 plus TNF-, 1nM rh 
thrombin (Cat. No. 1773SE, R&D Systems), 5 nM rh MMP-1(Cat. No. ab39297, Abcam, 
Cambridge, UK) or 100 μM cobalt chloride (CoCl2) (AVONCHEM limited, Macclesfield, 
Cheshire SK116PJ, United Kingdom) for 24 hours or with 30 mM glucose (Scharlau, 
Sentmenat, SPAIN) or 30 mM mannitol (Scharlau, Sentmenat, SPAIN) (as an osmotic 
control) for 72 hours. Wherever needed, cells were pre-treated for 30 minutes with the 
specific PAR1 inhibitor vorapaxar at a concentration of 10 μM (Cat. No. sc-394048 Santa 
Cruz Biotechnology Inc, Santa Cruz, CA). Each experiment was done at least three times 
with duplicate cell culture conditions. 
Enzyme-linked immunosorbent assays 
An enzyme-linked immunosorbent assay (ELISA) kit for human VEGF (Cat No: 
SVE00) was purchased from R&D Systems. ELISA kits for thrombin (Cat No: ab108909) 
and MMP-1 (Cat No: ab100603) were purchased from Abcam, Cambridge, UK. The 
thrombin ELISA kit recognizes both natural and recombinant human thrombin. The MMP-1 
ELISA kit detects human pro and active forms. The minimum detection limits for the VEGF, 
thrombin and MMP-1 ELISA kits were 9 pg/mL, 0.3 ng/mL and 8 pg/mL, respectively. The 
ELISA plate readings were done using a Stat Fax-4200 microplate reader from Awareness 
Technology, Inc., Palm City, FL.  
The quantification of human VEGF, Thrombin and MMP-1 in vitreous fluids was 
determined with the  use of commercially available ELISAs in accordance with the 
manufacturer’s instructions. For each ELISA, the undiluted standard served as the highest 
standard and calibrator diluents were used as the zero standard. Depending on the detection 
range for each ELISA kit, vitreous fluid samples were adequately diluted with calibrator 
diluents supplied with each ELISA kit. 
For the measurement of VEGF and MMP-1, 100 µl of undiluted vitreous samples 
were used. For the measurement of thrombin, 100 µl of 4-fold diluted vitreous samples were 
analyzed. As instructed in the manuals, samples were incubated into each well of the ELISA 
plates.  Antibodies against VEGF, thrombin and MMP-1 conjugated to horseradish 
peroxidase (HRP) were added to each well of the ELISA plates. After incubation, a substrate 
mix solution (1:1, hydrogen peroxide:tetramethylbenzidine ) was added for color 
development.  The reaction was stopped by the addition of 2N sulfuric acid (R & D Systems), 
and the optical density was read at 450 nm in a microplate reader. Each assay was performed 
in duplicate.  Using the 4-parameter fit logistic (4-PL) curve equation, the actual 
concentration of each sample was calculated. For the diluted vitreous fluids, the correction 
read from the standard curve obtained using 4-PL was multiplied by the dilution factor to 
calculate the actual reading for each sample.  
Western blot analysis for thrombin, MMP-1, PAR1 and VEGF 
Retinas from diabetic and control rats were homogenized in Western blot lysis buffer 
(30 mM Tris-HCl; pH 7.5, 5 mM EDTA, 1% Triton X-100, 250 mM sucrose, 1 mM Sodium 
vanadate and protease inhibitor cocktail). The protease inhibitor used was “Complete without 
EDTA” (Roche, Mannheim, Germany). The homogenates were centrifuged at 14,000g for 15 
minutes at 4°C and the supernatants were used for protein estimation and further analysis. 
HRMEC were lysed after harvest with RIPA buffer (50 mM Tris/HCl [pH 7.5], 150 mM 
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NaCl, 1% (v/v) Nonidet P40 (NP40), 0.5% Sodium deoxycholate, 0.1% SDS and protease 
inhibitor “Complete without EDTA” (Roche, Mannheim, Germany). Whole cell extracts 
from different treated groups were centrifuged at 12,000 ×g for 10 min at 4°C. The 
supernatants were collected and protein concentrations were measured with the use of DC 
protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein (50 
μg) were subjected to SDS-polyacrylamide gel (SDS-PAGE) electrophoresis in 8-10% gels 
and transferred onto  nitrocellulose membranes (Bio-Rad Laboratories). To determine the 
expression levels of thrombin and MMP-1 in the vitreous samples, equal volumes (15 μl) of 
vitreous samples were boiled in Laemmli’s sample buffer (1:1, v/v) under reducing 
conditions for 10 min and analyzed as described. Nonspecific binding sites were blocked (1.5 
hours, room temperature) with 5 % non-fat milk made in Tris-buffered saline containing 
0.1%Tween-20 (TBS-T)).   Blots were then incubated at 4
0
C overnight using the following 
primary antibodies; anti-thrombin (1:1000; ab-92621; Abcam), anti-MMP-1 (1:500; sc-
30069; Santa Cruz Biotechnology Inc, Santa Cruz, CA), anti-PAR1 (1:1000, mab-3855, R&D 
Systems) and anti-VEGF (1:500, Cat. No. MAB293 R&D Systems). Three TBS-T washings 
(5 min each) were performed prior to respective secondary antibody treatment at room 
temperature for 1 hour. Finally, the immunodetection was performed with the use of 
chemiluminescense Western blotting luminol reagent (sc-2048; Santa Cruz Biotechnology 
Inc). Membranes were stripped and reprobed with β-actin-specific antibody (1:2000; sc-
47778; Santa Cruz Biotechnology Inc) used as the lane-loading control. Bands were 
visualized with the use of a high-performance chemiluminescence machine (G: Box Chemi-
XX8 from Syngene, Synoptic Ltd. Cambridge, UK), and the intensities were quantified by 
using GeneTools software (Syngene by Synoptic Ltd.).  
In vitro migration assay  
HRMEC were plated at 1×10
5
 cells/well on 6-well culture plates and allowed to grow 
as described above till 80–90% confluency. Quiescence was induced by incubating the cells 
in minimal media overnight. Scratches were made with a sterile pipette tip and then cells 
were rinsed with PBS. Cells were either left untreated or treated either with 1nM thrombin or 
5nM MMP-1 or with 10 μM vorapaxar for 30 minutes before addition of thrombin, and then 
cells were incubated for further 16 hours. Cell migration was monitored by visual 
examination using an inverted microscope (Olympus 1X 81). Analysis of migration was done 
using Image J software. 
Immunohistochemical staining 
For CD31, -smooth muscle actin (-SMA) and PAR1, antigen retrieval was 
performed by boiling the sections in citrate based buffer [pH 5.9 – 6.1] [BOND Epitope 
Retrieval Solution 1; Leica] for 10 minutes. For CD45 detection, antigen retrieval was 
performed by boiling the sections in Tris/EDTA buffer [pH 9] [BOND Epitope Retrieval 
Solution 2; Leica] for 20 minutes.  Subsequently, the sections were incubated for 60 minutes 
with mouse monoclonal anti-CD31 (ready-to-use; clone JC70A; Dako, Glostrup, Denmark), 
mouse monoclonal anti-CD45 (ready-to-use; clones 2B11+PD7/26; Dako), mouse 
monoclonal anti--smooth muscle actin (ready-to-use; clone 1A4; Dako) and rabbit 
polyclonal anti-PAR1 antibody (1:200, APR-031, Alomone Labs, Jerusalem, Israel). Optimal 
working concentrations and incubation times for the antibodies were determined earlier in 
pilot experiments on sections from placenta and from patients with glioblastoma. The 
sections were then incubated for 20 minutes with a post primary IgG linker followed by an 
alkaline phosphatase conjugated polymer. The reaction product was visualized by incubation 
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for 15 minutes with the Fast Red chromogen, resulting in bright-red immunoreactive sites. 
The slides were then faintly counterstained with Mayer’s hematoxylin [BOND Polymer 
Refine Red Detection Kit; Leica].  
To identify the phenotype of cells expressing PAR1, sequential double 
immunohistochemistry was performed. The sections were incubated with the first primary 
antibody (anti-CD45) and subsequently treated with peroxidase conjugated secondary 
antibody. The sections were visualized with 3, 3’-diaminobenzidine tetrahydrochloride. 
Incubation of the second primary antibody (anti-PAR1) was followed by treatment with 
alkaline phosphatase conjugated secondary antibody. The sections were visualized with fast 
red. No counterstain was applied. 
Omission or substitution of the primary antibody with an irrelevant antibody from the 
same species (rabbit monoclonal anti-human estrogen receptor α; ready-to-use; clone EPI, 
Dako) and staining with chromogen alone were used as negative controls. 
Statistical analysis 
 Data are presented as the mean ± standard deviation. The non-parametric Mann-
Whitney test was used to compare means from two independent groups. The Chi-square test 
was used for comparing proportions when analyzing data for two categorical variables. 
Pearson correlation coefficients were computed to investigate correlation between variables. 
A p-value less than 0.05 indicated statistical significance. SPSS version 20.0 for Windows 
(IBM Inc., Chicago, IL, USA) was used for statistical analysis. 
 
 
Results 
 
ELISA levels of thrombin, MMP-1 and VEGF in vitreous samples 
 With the use of ELISA, we demonstrated that thrombin was detected in all vitreous 
samples from patients with PDR and nondiabetic control patients. The mean thrombin level 
in vitreous samples from PDR patients (7.7±3.0 ng/ml) was significantly higher than the 
mean level in nondiabetic control patients (4.9±4.0 ng/ml) (p=0.012; Mann-Whitney test). 
MMP-1 was not detected in vitreous samples from nondiabetic control patients. However, 
MMP-1 was detected in 12 of 30 (40%) vitreous samples from patients with PDR. The mean 
MMP-1 level in vitreous samples from PDR patients (39.9±164.01 pg/ml) (range, 8-901 
pg/ml) was significantly higher than the mean level in nondiabetic control patients (p=0.002; 
Mann-Whitney test). VEGF was detected in 11 of 22 (50%) vitreous samples from 
nondiabetic control patients, and in all vitreous samples from patients with PDR (n=24) 
(p=0.0003; Chi-square test). The mean VEGF level in vitreous samples from PDR patients 
(650.6±986.3 pg/ml) was significantly higher than that in nondiabetic control patients 
(25.6±59.9 pg/ml) (p<0.0001; Mann-Whitney test). 
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Correlations 
Significant positive correlations were found between vitreous fluid levels of thrombin 
and levels of VEGF (r=0.41; p=0.006). A significant positive correlation was observed 
between vitreous fluid levels of MMP-1 and VEGF (r=0.66; p<0.0001) (Fig. 1). In contrast, 
the correlation between vitreous fluid levels of thrombin and MMP-1 was not significant.  
Western blot analysis of vitreous samples 
 With the use of Western blot analysis of equal volumes (15 μL) of vitreous samples, 
we confirmed that thrombin and MMP-1 were expressed in vitreous samples. Thrombin 
protein migrated as two protein bands on SDS-PAGE when immunoblotted and analyzed 
with the specific antibody. The upper band corresponded to the zymogen prothrombin 
(approximately 70 kDa), whereas the lower protein band corresponded to the proteolytically 
active thrombin (approximately 50 kDa) (Fig. 2A). When MMP-1 was analyzed by Western  
blot, we observed that MMP-1 protein migrated as two protein bands at approximately 60 
kDa (proMMP-1) and approximately 50 kDa (activated form of MMP-1) (Fig 2B).   
Immunohistochemical analysis of epiretinal membranes 
 To identify the cell types expressing PAR1, epiretinal membranes from patients with 
PDR were studied by immunohistochemical analysis. No staining was observed in the 
negative control slides (Fig. 3A). All membranes showed blood vessels that were positive for 
the endothelial cell marker CD31 (Fig. 3B). Strong immunoreactivity for PAR1 was present 
in all membranes and was noted in vascular endothelial cells, stromal cells and intravascular 
leukocytes (Fig. 3C, D, E). In serial sections, the distribution and morphology of stromal cells 
expressing PAR1 were similar to those of cells expressing the leukocyte common antigen 
CD45 (Fig. 3F). In addition, the distribution and morphology of spindle-shaped stromal cells 
expressing PAR1 (Fig. 3E) were similar to those of spindle-shaped stromal cells expressing 
the myofibroblast marker -SMA (Fig. 3G). Double staining confirmed that stromal 
leukocytes and intravascular leukocytes expressing PAR1 co-expressed CD45 (Fig. 3H). 
The proinflammatory cytokines IL-1 and TNF-, but not high-glucose and the hypoxia 
mimetic agents CoCl2 induce upregulation of PAR1 in HRMEC. 
 To confirm the observed expression of PAR1 by endothelial cells, we performed 
induction experiments on HRMEC with inducers relevant in the context of PDR such as high-
glucose, proinflammatory cytokines and hypoxia. Thus, we treated the HRMEC either with 
30 mM glucose or 30 mM mannitol for 72 hours or for 24 hours with 10 ng/ml IL-1, 30 
ng/ml TNF-, IL-1 plus TNF- or 100 μM CoCl2 and compared the levels of expression of 
PAR1 in whole cell extracts by Western blot analysis.  
 PAR1 protein migrated as three prominent protein bands on SDS-PAGE when 
immunoblotted and analyzed with specific antibody. The upper band corresponded to the 
intact protein (approximately 65 kDa), whereas the lower protein bands corresponded to 
cleaved PAR1 (approximately 50 kDa and 30 kDa). Densitometric analysis of the bands 
demonstrated a significant  increase in the 30-kDa fragment expression and in the ratios of 
the 30-kDa fragment over the full length protein in response to IL-1, TNF- or IL-1 plus 
TNF-. In contrast, the expression of the full length protein (approximately 65 kDa) and the 
50-kDa fragment did not change (Fig. 4). Treatment of HRMEC with high-glucose and CoCl2 
did not affect the expression of PAR1 as compared to untreated control (data not shown). 
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Severity of hyperglycemia and effect of diabetes on retinal expression of PAR1 and 
thrombin in experimental rats 
 To validate our observations and to obtain a better view of the studied molecules in 
the pathogenesis of diabetic retinopathy, we used a rat animal model. After induction of 
diabetes with a single high-dose of streptozotocin, the body weights of the diabetic rats were 
significantly lower and their blood glucose values were more than four-fold higher compared 
with age-matched normal control rats (164 ± 28 versus 297 ± 19 g and 458 ± 24 versus 107 ± 
14 mg/dl, respectively). Western blot analysis of homogenized retinal tissue demonstrated 
that PAR1 protein migrated as two protein bands at approximately 65 kDa and 50 kDa. 
Thrombin protein migrated as two protein bands at approximately 70 kDa and 50 kDa. 
Densitometric analysis of the bands demonstrated that the ratios of the cleaved PAR 1 
(approximately 50 kDa) over the intact protein (approximately 65 kDa) and of the 
proteolytically active thrombin (approximately 50 kDa) over the zymogen prothrombin 
(approximately 70 kDa) were significantly higher in the retinas of diabetic rats compared to 
the retinas of nondiabetic control rats (n=7) (Fig. 5).  
Thrombin and MMP-1 induce upgregulation of VEGF in HRMEC 
 To confirm the significant positive correlation between the vitreous fluid levels of 
thrombin and MMP-1 with those of the angiogenic biomarker VEGF, we performed 
induction experiments on HRMEC with thrombin and MMP-1. HRMEC were stimulated for 
24 hours with 1nM rh thrombin or 5nM rh MMP-1, and we compared the levels of expression 
of VEGF in the whole cell extracts by Western blot analysis. We found that both thrombin 
and MMP-1 treatments significantly increased the expression of VEGF (Fig. 6). Vorapaxar 
pre-treatment did not inhibit upregulation of VEGF induced by thrombin (data not shown). 
The PAR1 inhibitor vorapaxar inhibits thrombin-induced migration in HRMEC 
 Next we tested the effect of PAR1 on thrombin-induced in vitro migration in 
HRMEC. For this purpose, we used the specific PAR1 inhibitor vorapaxar. HRMEC were left 
untreated or treated either with thrombin or with vorapaxar for 30 minutes before addition of 
thrombin and in vitro migration was analyzed. Our data convincingly showed that vorapaxar 
pre-treatment significantly inhibited the migration induced by thrombin in HRMEC (Fig. 7). 
These results provided evidence that PAR1 signaling is involved in the migration induced by 
thrombin in HRMEC. On the other hand, MMP-1 did not induce migration in HRMEC (Fig. 
7).  
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      Discussion 
 Activation of PAR1 signaling in endothelial cells induces both their proliferation and 
recruitment and promotes angiogenesis by increasing the expression, activation and secretion 
of angiogenic growth factors such as VEGF [10, 15]. The expression of PAR1 in tumor cells 
is sufficient to induce functional VEGF expression levels, eliciting tumor angiogenesis both 
in vivo in animal models and in vitro (as shown by the endothelial tube forming assay and 
cell migration) [17, 18]. In addition, PAR1 is required in endothelial cells for maturation and 
stabilization of the blood vessels [17]. Inhibition of PAR1 resulted in decreased expression of 
VEGF and decreased blood vessel density in melanoma tumors [10].  
In the present study, we investigated this signaling cascade in diabetic retinopathy and 
showed, for the first time, that PAR1 immunoreactivity was specifically localized in vascular 
endothelial cells, leukocytes expressing the leukocyte common antigen CD45, and 
myofibroblasts in epiretinal fibrovascular membranes from patients with PDR. Our data are 
in line of those of others, who have shown that PAR1 is expressed by a variety of cell types 
in the tumor microenvironment, including endothelial cells, platelets, macrophages, and 
fibroblasts [10]. Furthermore, we showed that cleaved PAR1 (approximately 50 kDa) was 
significantly upregulated in the retinas of diabetic rats. To corroborate the findings at the 
cellular level, stimulation with the proinflammatory cytokines IL-I and TNF- caused 
upregulation of cleaved PAR1 (approximately 30 kDa) in HRMEC. On the other hand, high-
glucose and the hypoxia mimetic agent CoCl2 did not affect the expression of PAR1 in 
HRMEC. Taken together, these findings suggest that inflammation, but not hyperglycemia 
and hypoxia might be involved in diabetes-induced PAR1 upregulation, which might be a 
chief pathophysiologic mechanism for diabetic retinopathy.  It was demonstrated that 
cleavage of PAR1 reveals a new amino terminus domain that functions as a tethered ligand 
by binding to its receptor and initiates downstream signaling [10-12]. These findings are 
consistent with previous studies that demonstrated upregulation of PAR1 in the kidney of 
diabetic mice [20], and that advanced glycation end-products, thought to play a pivotal role in 
the pathogenesis of diabetic retinopathy [21], increase PAR1 expression in endothelial cells 
[22]. Taken together, these findings suggest that diabetes-induced retinal endothelial 
structural damage leads to their proliferation and sprouting by inducing PAR1 expression, 
which might be a chief pathophysiologic mechanism in PDR.   
 Thrombin is a serine protease that is generated from its inactive precursor 
prothrombin. In addition to its central role in the coagulation cascade via platelet activation 
and fibrin deposition, thrombin is a key supporter of various cellular effects, relevant for 
tumor growth and metastasis, as well as a potent activator of angiogenesis. The main 
mechanism responsible for these cellular actions of thrombin is mediated by PAR1 which has 
been shown to respond with high affinity to thrombin [12, 23, 24]. Angiogenesis involves the 
activation and invasion of endothelial cells through their basement membrane, proliferation 
and migration to distal sites. It has been demonstrated that thrombin contributes to each of 
these events through PAR1 signaling [12, 24] and that PAR1 antagonists are very potent anti-
angiogenic agents [12]. In addition, thrombin has a potent anti-apoptotic effect on serum-
starved endothelial cells [25]. Several vascular regulatory proteins and growth factors have 
been shown to be activated or upregulated by thrombin. For example, thrombin-induced 
angiogenesis is associated with upregulation of VEGF. Thrombin increased VEGF levels in 
several cell types, such as endothelial cells and it induced VEGF receptor-2 expression in 
endothelial cells. Another important effect of thrombin is the potentiation of the mitogenic 
activity of VEGF on endothelial cells [12, 15, 23-26]. 
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 In the present study, we showed for the first time that a procoagulant condition is 
created in the eye by diabetes, because thrombin was significantly upregulated in the vitreous 
fluid from patients with PDR and in the retinas of diabetic rats. In addition, we found a 
significant positive correlation between the vitreous fluid levels of thrombin and those of the 
angiogenic biomarker VEGF, a key angiogenic factor in PDR [4], and that stimulation with 
thrombin caused upregulation of VEGF in HRMEC. It should be emphasized that thrombin 
and VEGF were detected in all and 50%, respectively, of vitreous samples from patients with 
rhegmatogenous retinal detachment with no proliferative vitreoretinopathy. These findings 
are consistent with  previous reports that demonstrated upregulated expression of 
inflammatory mediators in the vitreous fluid from patients with rhegmatogenous retinal 
detachment [27-29] and in the detached retina following experimental retinal detachment 
[30].  The present findings are consistent with previous studies that demonstrated active 
involvement of thrombin in the upregulation of VEGF expression in several cell lines [12, 15, 
23-26]. The results of the present study also show that vorapaxar, a potent PAR1 receptor  
antagonist [19], inhibited HRMEC migration, a key early step in angiogenesis, induced by 
thrombin. Together, these results provide evidence that thrombin and its receptor PAR1 
might  mediate angiogenesis in PDR. Furthermore, several studies demonstrated that 
thrombin activation mediates intracerebral hemorrhage-induced neurotoxicity and severe 
blood-brain barrier disruption and neuronal cell death during brain ischemia [31-34]. The 
direct cytotoxic effects of thrombin appear to be mediated by PAR1 [31, 32].  
 MMP-1 is an interstitial collagenase that is often upregulated in several types of 
cancer, and this enzyme is involved in tumor-induced angiogenesis [14, 35-38]. Purified  
MMP-1 is also capable of inducing angiogenesis in vivo, thereby defining MMP-1 as a pro-
angiogenic factor [14]. Recently, Boire et al [13] showed that MMP-1 is an additional 
proteolytic activator of PAR1, promoting angiogenesis, invasion and tumorigenesis of cancer 
cells in vitro and in vivo. The pro-angiogenic effects of MMP-1 are significantly reduced 
when PAR1 activation is inhibited [13, 14]. Further, activation of endothelial cells by MMP-1 
[14], and of cancer cells [16] via PAR1 induces the secretion of several angiogenic factors. 
Furthermore, the combination of thrombin and MMP-1 is more angiogenic than either 
protease alone [14]. In addition, tumor-derived MMP-1 activates endothelial PAR1 to induce 
disruption of the vascular endothelial barrier and increases vascular permeability [39], a 
characteristic sign of diabetic retinopathy [40]. In the current study, we found that MMP-1 
was significantly upregulated in the vitreous fluid from patients with PDR and that there was 
a significant positive correlation between the levels of MMP-1 and VEGF. To corroborate the 
findings at the cellular level, stimulation with MMP-1 caused upregulation of VEGF in 
HRMEC.  
 In conclusion, our data provide evidence that PAR1, thrombin and MMP-1 are 
expressed within the ocular microenvironment of patients with PDR and show that PAR1 and 
thrombin might facilitate angiogenesis and progression of PDR by inducing endothelial cell 
migration, as well as secretion of angiogenic mediators. These findings suggest that this 
signaling axis may present a new avenue for therapeutic intervention in patients with diabetic 
retinopathy. 
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Figure 1. Significant positive correlations between vitreous fluid levels of thrombin and the 
levels of vascular endothelial growth factor (VEGF) (A) and between the vitreous 
fluid levels of MMP-1 and the levels of VEGF (B). 
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Figure 2. The expressions of thrombin (A) and matrix metalloproteinase-1 (MMP-1) (B) in 
equal volumes (15 μL) of vitreous samples from patients with proliferative diabetic 
retinopathy (PDR) and from control patients without diabetes (C) were determined 
by Wastern blot analysis. Thrombin protein migrated as two protein bands on SDS-
PAGE when immunoblotted and analyzed with the specific antibody. The upper 
band corresponded to the zymogen prothrombin (approximately 70 kDa), whereas 
the lower protein band corresponded to the proteolytically active thrombin 
(approximately 50 kDa). MMP-1 protein migrated as two protein bands at 
approximately 60 kDa (proMMP-1) and approximately 50 kDa (activated MMP-1) 
Representative set of samples are shown.  
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Figure 3. Proliferative diabetic retinopathy epiretinal membranes. Negative control slide that 
was treated identically with an irrelevant antibody showing no labeling (A). 
Immunohistochemical staining for CD31 showing blood vessels positive for CD31 
(B). Immunohistochemical staining for protease-activated receptor-1 (PAR1) 
showing immunoreactivity in the vascular endothelium (arrows), in stromal cells 
(arrowheads) (C), in intravascular leukocytes (arrowheads) (D) and in stromal 
spindle-shaped cells (E). Immunohistochemical staining for CD45 showing stromal 
cells positive for CD45 (F). Immunohistochemical staining for -smooth muscle 
actin showing immunoreactivity in spindle-shaped myofibroblasts (G). Double 
immunohistochemistry for CD45 (brown) and PAR1 (red) showing stromal cells and 
intravascular leukocytes (arrowheads) co-expressing CD45 and PAR1 (H) (original 
magnification X40). 
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Figure 4. Human retinal microvascular endothelial cells were left untreated or were treated 
with either IL-1 (10 ng/ml), TNF- (30 ng/ml), or with a combination of cytokines 
containing IL-1 (10 ng/ml) plus TNF- (30 ng/ml) for 24 hours. The levels of 
expression of protease-activated receptor-1 (PAR1) were compared by Western blot 
analysis. Western blots are representative of at least three independent experiments, 
each is performed in duplicate and bar graphs are representative of all three 
experiments. *P <0.05 compared to untreated control. 
#
P <0.05 compared to IL-1. 
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Figure 5. Western blot analysis of protease-activated receptor-1 (PAR1) (A) and thrombin 
(B) in rat retinas. Significant increases in the ratios of the cleaved PAR1 over the 
intact protein and of the proteolytically active thrombin over the zymogen 
prothrombin in the retinas of diabetic rats (D) compared to the nondiabetic control 
rats (C). Each experiment was repeated 3 times with fresh samples (n=7). *P <0.05 
compared to control.   
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Figure 6. Effects of thrombin (A) and matrix metalloproteinase-1 (MMP-1) (B) on the 
expression of vascular endothelial growth factor (VEGF) in human retinal 
microvascular endothelial cells. Protein expression of VEGF in treated and untreated 
(control) cell lysates was determined by Western blot analysis. Western blots are 
representative of at least three independent experiments, each is performed in 
duplicate and bar graphs are representative of all three experiments. *P <0.05 
compared to untreated control.  
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Figure 7.  Effects of thrombin (A) and matrix metalloproteinase -1 (MMP-1) (B) on 
migration of human retinal microvascular endothelial cells (HRMEC). Thrombin-
induced migration of HRMEC was inhibited by the protease-activated receptor-1 
(PAR1) inhibitor vorapaxar. HMREC were left untreated or treated either with 1nM 
22 
 
recombinant thrombin, with 10 µM PAR1 inhibitor vorapaxar for 30 minutes before 
addition of 1nM recombinant thrombin or with 5 nM recombinant MMP-1. Cells 
were visualized using inverted microscope (Olympus 1X 81, Olympus Corporation, 
Tokyo, Japan). Three independent experiments were performed. Six independent 
field images were taken from each treated group for migration analysis which was 
done by using Image J software. One image from each group is illustrated and the 
bar graphs show the analysis of all six images from each group. *P <0.05 compared 
to untreated control. 
#
P <0.05 compared to vorapaxar + thrombin.  
